These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8654625)

  • 21. Long-term administration of tibolone plus gonadotropin-releasing hormone agonist for the treatment of uterine leiomyomas: effectiveness and effects on vasomotor symptoms, bone mass, and lipid profiles.
    Palomba S; Affinito P; Di Carlo C; Bifulco G; Nappi C
    Fertil Steril; 1999 Nov; 72(5):889-95. PubMed ID: 10560995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs.
    Mittan D; Lee S; Miller E; Perez RC; Basler JW; Bruder JM
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3656-61. PubMed ID: 12161491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome.
    Mitwally MF; Gotlieb L; Casper RF
    Menopause; 2002; 9(4):236-41. PubMed ID: 12082359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immediate and delayed add-back hormonal replacement therapy during ultra long GnRH agonist treatment of chronic cyclical pelvic pain.
    Al-Azemi M; Jones G; Sirkeci F; Walters S; Houdmont M; Ledger W
    BJOG; 2009 Nov; 116(12):1646-56. PubMed ID: 19735378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
    Michaelson MD; Kaufman DS; Lee H; McGovern FJ; Kantoff PW; Fallon MA; Finkelstein JS; Smith MR
    J Clin Oncol; 2007 Mar; 25(9):1038-42. PubMed ID: 17369566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initiation of GnRH agonist treatment on 3-5 days postoperatively in endometriosis patients: a randomized controlled trial.
    Gong L; Zhang S; Han Y; Long Q; Zou S; Cao Y
    J Clin Pharmacol; 2015 Aug; 55(8):848-53. PubMed ID: 25694383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up.
    Surrey ES; Hornstein MD
    Obstet Gynecol; 2002 May; 99(5 Pt 1):709-19. PubMed ID: 11978277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gonadotropin-releasing hormone agonist plus "add-back" hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial.
    Franke HR; van de Weijer PH; Pennings TM; van der Mooren MJ
    Fertil Steril; 2000 Sep; 74(3):534-9. PubMed ID: 10973651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of tibolone as "add-back therapy" in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids.
    Morris EP; Rymer J; Robinson J; Fogelman I
    Fertil Steril; 2008 Feb; 89(2):421-8. PubMed ID: 17572410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Long-term observations of the extent and reversibility of bone demineralization after leuprorelin acetate depot therapy].
    Spitz J; Hoffmann G
    Zentralbl Gynakol; 1996; 118(4):198-205. PubMed ID: 8651006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effectiveness and tolerance of a gonadotropin releasing hormone (goserelin) in treatment of symptomatic endometriosis].
    Wenzl R; Schultes G; Stummvoll W; Wieser F; Husslein P
    Wien Klin Wochenschr; 1999 Apr; 111(7):283-8. PubMed ID: 10355039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone "add-back" therapy.
    Surrey ES; Voigt B; Fournet N; Judd HL
    Fertil Steril; 1995 Apr; 63(4):747-55. PubMed ID: 7890057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of six months of GnRH agonist therapy for endometriosis. Is there an age-related effect on bone mineral density?
    Agarwal SK
    J Reprod Med; 2002 Jul; 47(7):530-4. PubMed ID: 12170527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of pelvic endometriosis with goserelin, an LHRH agonist].
    Ventruba P; Crha I; Müller P; Mlyncek M
    Ceska Gynekol; 1996 Feb; 61(1):11-6. PubMed ID: 8624587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Bone fracture receiving LH-RH agonists for prostatic cancer].
    Hatano T; Igarashi H; Nakada J; Oishi Y; Yanada S; Furuta A; Takizawa A; Iwamuro S; Tashiro K
    Nihon Hinyokika Gakkai Zasshi; 2000 Jun; 91(6):542-6. PubMed ID: 10897579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Add-back therapy in the treatment of endometriosis-associated pain.
    Zupi E; Marconi D; Sbracia M; Zullo F; De Vivo B; Exacustos C; Sorrenti G
    Fertil Steril; 2004 Nov; 82(5):1303-8. PubMed ID: 15533351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency.
    Finkelstein JS; Klibanski A; Schaefer EH; Hornstein MD; Schiff I; Neer RM
    N Engl J Med; 1994 Dec; 331(24):1618-23. PubMed ID: 7969342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Case report: systemic hypersensitivity reaction to goserelin acetate.
    Raj SG; Karadsheh AJ; Guillot RJ; Raj MH; Kumar P
    Am J Med Sci; 1996 Oct; 312(4):187-90. PubMed ID: 8853068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prevention of bone loss in young women treated with GnRH analogues with "add-back" estrogen therapy.
    Leather AT; Studd JW; Watson NR; Holland EF
    Obstet Gynecol; 1993 Jan; 81(1):104-7. PubMed ID: 8416441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alendronate for the prevention of bone mineral loss during gonadotropin-releasing hormone agonist therapy.
    Ripps BA; VanGilder K; Minhas B; Welford M; Mamish Z
    J Reprod Med; 2003 Oct; 48(10):761-6. PubMed ID: 14619641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.